We provide engineered cellular models targeting novel immune checkpoint molecules, including BDCA2, CD24, and VSIG4. These standardized reporter systems enable efficient evaluation of target activation/inhibition activity, supporting the screening and mechanistic study of immunomodulators. They offer reliable tools for drug development in cancer immunotherapy and autoimmune diseases.
